Metastatic signet-ring cell cancer of the bladder responding to chemotherapy with capecitabine: case report and review of literature

Por Michels, Jorg, Barbour, Sean, Cavers, Douglas, Chi, Kim N.
Publicado em 2010

Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions

Por Heng, Daniel Y.C., Kollmannsberger, Christian, Chi, Kim N.
Publicado em 2010

Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer

Por Zielinski, Robert R., Azad, Arun A., Chi, Kim N., Tyldesely, Scott
Publicado em 2014

Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen

Por Blumenstein, Brent, Saad, Fred, Hotte, Sebastien, Chi, Kim N, Eigl, Bernhard, Gleave, Martin, Jacobs, Cindy
Publicado em 2013

Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer

Por Watahiki, Akira, Macfarlane, Robyn J., Gleave, Martin E., Crea, Francesco, Wang, Yuzhuo, Helgason, Cheryl D., Chi, Kim N.
Publicado em 2013

Morphological Differences between Circulating Tumor Cells from Prostate Cancer Patients and Cultured Prostate Cancer Cells

Por Park, Sunyoung, Ang, Richard R., Duffy, Simon P., Bazov, Jenny, Chi, Kim N., Black, Peter C., Ma, Hongshen
Publicado em 2014

PD-L1 is highly expressed in Enzalutamide resistant prostate cancer

Por Bishop, Jennifer L., Sio, Alexander, Angeles, Arkhjamil, Roberts, Morgan E., Azad, Arun A., Chi, Kim N., Zoubeidi, Amina
Publicado no Oncotarget (2014)

Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada

Por Pataky, Reka, Gulati, Roman, Etzioni, Ruth, Black, Peter, Chi, Kim N., Coldman, Andrew J., Pickles, Tom, Tyldesley, Scott, Peacock, Stuart
Publicado no Int J Cancer (2014)

Frequent mutation of the FOXA1 untranslated region in prostate cancer

Por Annala, Matti, Taavitsainen, Sinja, Vandekerkhove, Gillian, Bacon, Jack V. W., Beja, Kevin, Chi, Kim N., Nykter, Matti, Wyatt, Alexander W.
Publicado no Commun Biol (2018)

A Phase 2 Study of GW786034 (Pazopanib) with or without Bicalutamide in Patients with Castration Resistant Prostate Cancer

Por Sridhar, Srikala S., Joshua, Anthony M., Gregg, Richard, Booth, Christopher M., Murray, Nevin, Golubovic, Jovana, Wang, Lisa, Harris, Pamela, Chi, Kim N.
Publicado no Clin Genitourin Cancer (2014)

A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: Factors associated with treatment completion

Por Parimi, Sunil, Tsang, Erica, Alexander, Abraham, McKenzie, Michael, Bachand, Francois, Sunderland, Katherine, Chi, Kim N., Aparicio, Maria, Worsley, Daniel, Tyldesley, Scott
Publicado no Can Urol Assoc J (2017)

Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II tria...

Por Leibowitz-Amit, Raya, Pintilie, Melania, Khoja, Leila, Azad, Arun A., Berger, Raanan, Laird, A. Douglas, Aftab, Dana T., Chi, Kim N., Joshua, Anthony M.
Publicado no J Transl Med (2016)

Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer

Por Taavitsainen, Sinja, Annala, Matti, Ledet, Elisa, Beja, Kevin, Miller, Patrick J., Moses, Marcus, Nykter, Matti, Chi, Kim N., Sartor, Oliver, Wyatt, Alexander W.
Publicado no JCO Precis Oncol (2019)

CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update

Por Saad, Fred, Hotte, Sebastien, Catton, Charles, Drachenberg, Darrel, Finelli, Antonio, Fleshner, Neil, Gleave, Martin, Kapoor, Anil, Kassouf, Wassim, Loblaw, Andrew, North, Scott, Usmani, Nawaid, Chi, Kim N.
Publicado em 2013

Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone

Por Ryan, Charles J., Kheoh, Thian, Li, Jinhui, Molina, Arturo, De Porre, Peter, Carles, Joan, Efstathiou, Eleni, Kantoff, Philip W., Mulders, Peter F.A., Saad, Fred, Chi, Kim N.
Publicado no Clin Genitourin Cancer (2017)

Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer

Por So, Alan I., Chi, Kim N., Danielson, Brita, Fleshner, Neil E., Kapoor, Anil, Niazi, Tamim, Pouliot, Frederic, Rendon, Ricardo A., Shayegan, Bobby, Sridhar, Srikala, Vigneault, Eric, Saad, Fred
Publicado no Can Urol Assoc J (2020)

Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists

Por Hsu, Tina, Black, Peter C., Chi, Kim N., Canil, Christina M., Eigl, Bernhard J., Kulkarni, Girish, North, Scott, Wood, Lori, Zlotta, Alexandre R., Lau, Anthea, Panzarella, Tony, Sridhar, Srikala S.
Publicado em 2014

A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate

Por Khalaf, Daniel Joseph, Avilés, Claudia M., Azad, Arun A., Sunderland, Katherine, Todenhöfer, Tilman, Eigl, Berhard J., Finch, Daygen, Le, Lyly, Atwell, Andrew, Keith, Bruce, Kollmannsberger, Christian, Chi, Kim. N.
Publicado no Can Urol Assoc J (2018)

The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)

Por Saad, Fred, Chi, Kim N., Finelli, Antonio, Hotte, Sebastien J., Izawa, Jonathan, Kapoor, Anil, Kassouf, Wassim, Loblaw, Andrew, North, Scott, Rendon, Ricardo, So, Alan, Usmani, Nawaid, Vigneault, Eric, Fleshner, Neil E.
Publicado no Can Urol Assoc J (2015)

Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies

Por Obst, Jon K., Wang, Jun, Jian, Kunzhong, Williams, David E., Tien, Amy H., Mawji, Nasrin, Tam, Teresa, Yang, Yu Chi, Andersen, Raymond J., Chi, Kim N., Montgomery, Bruce, Sadar, Marianne D.
Publicado no ACS Pharmacol Transl Sci (2019)